Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis

Brian D Kent; Grainne d'Ancona; Mariana Fernandes; Linda Green; Cris Roxas; Louise Thomson; Alexandra M Nanzer; Joanne Kavanagh; Sangita Agarwal; David J Jackson

doi:10.1183/23120541.00311-2019

Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis

ERJ Open Res. 2020 Jan 20;6(1):00311-2019. doi: 10.1183/23120541.00311-2019. eCollection 2020 Jan.

Authors

Brian D Kent^{1

2}, Grainne d'Ancona^{1

2}, Mariana Fernandes¹, Linda Green¹, Cris Roxas¹, Louise Thomson¹, Alexandra M Nanzer^{1

2}, Joanne Kavanagh¹, Sangita Agarwal³, David J Jackson^{1

2}

Affiliations

¹ Guy's Severe Asthma Centre, Guy's and St Thomas' Hospitals, London, UK.
² Asthma UK Centre, King's College London, London, UK.
³ Dept of Rheumatology, Guy's and St Thomas' Hospitals, London, UK.

Abstract

Blockade of interleukin-5 with reslizumab appears to have significant oral corticosteroid sparing effects in patients with eosinophilic granulomatosis with polyangiitis and severe eosinophilic asthma http://bit.ly/2D2yYSK.